TEVA Stock — Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited (TEVA)

Updated October 16, 2026.

TEVA is a Stock. Total return is 11241.9% over the past 44.7 years.

Teva Pharmaceutical Industries Limited develops, manufactures, and distributes generic medicines, specialty pharmaceuticals, and biopharmaceutical products globally, with a focus on central nervous system, respiratory, and oncology treatments. The company does not currently distribute to shareholders. Teva operates as a traditional operating company with no expense ratio, appealing primarily to investors seeking equity exposure to the pharmaceutical sector rather than income-focused portfolios.

TEVA performance

Price and return data through 2026-10-16.

Total return is 11241.9% over the past 44.7 years. Over the past year its total return — price change plus distributions reinvested — is 111.4%. Its deepest 1-year drawdown was 21.8%.

TEVA key facts

Asset type

Stock

Asset class

Equity

Inception date

02/16/1982

Distribution frequency

None

5-year average yield

1.79

Last close

$41.50 (as of 2026-10-16)

Market cap

$48,401,144,684

Average volume

5936551.0

Ex-dividend date

11/28/2017

Payment date

12/12/2017

Beta

0.817

Payout ratio

0.0%

P/E ratio

69.17

Forward P/E

7.0472

EPS

$0.60

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TEVA risks and drawbacks

The deepest 1-year drawdown on record here is 21.8%.

Who may consider TEVA — and who may not

It is a weaker fit for investors who need monthly cash flow (TEVA does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on TEVA

• All tickers starting with T

Tagged: Healthcare, Pharmaceutical.

Frequently asked questions